Other Events ·
At its Annual Meeting on June 23, 2026, Spero Therapeutics stockholders approved an amendment to the Amended and…
SPROSpero Therapeutics, Inc.
At its Annual Meeting on June 23, 2026, Spero Therapeutics stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from 120,000,000 to 240,000,000. Stockholders also approved the 2026 Stock Incentive Plan, which allows for the issuance of up to 12,895,866 shares of common stock. The company operates in the biotechnology industry and develops therapies for infectious diseases.